Remove clinical prep
article thumbnail

PrEP Initiation, Continuation Feasible in Range of Clinical Settings

Pharmacy Times

Wide-ranging options for HIV pre-exposure prophylaxis initiation in different settings and though different providers should be maintained to ensure underserved populations get adequate treatment options.

40
article thumbnail

Semi-Annual PrEP Dispensing with HIV Self-Testing Resulted in Continued Adherence After 12 Months

Pharmacy Times

Six-month preexposure prophylaxis (PrEP) dispensing supported by HIV self-testing resulted in PrEP adherence after 12 months and less visits to clinical sites.

49
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Culturally Tailored Approaches Needed to Improve Access to PrEP for HIV

Pharmacy Times

Despite an increase in HIV and poorer clinical outcomes among migrant populations, the uptake of PrEP among these individuals has been understudied.

26
article thumbnail

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

Legacy MEDSearch

Newly cleared product enhancements include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures of calcium and external elastic lamina (EEL), and hands-free angiographic co-registration.

article thumbnail

Automated Mass Spec Technique to Detect Antidepressants

Medgadget

This new system requires very small sample volumes, and employs a robot liquid handling system that is commonly found in clinical mass spectrometry labs to nearly entirely automate the assay. Moreover, the time consuming manual sample prep steps are now conducted automatically by a robotic liquid handling system.

article thumbnail

FDA grants approval for Gilead’s multi-drug resistant HIV-1 treatment

Pharmaceutical Technology

This approval is backed by findings from the multicentre, double-blinded, placebo-controlled, international Phase II/III CAPELLA clinical trial of lenacapavir plus an optimised background regimen. The treatment is indicated for adult patients who are heavily treatment-experienced (HTE) with multi-drug resistant (MDR) HIV-1 infection.

article thumbnail

Vertex, CRISPR prep filing for gene-editing blood disorder therapy

pharmaphorum

Clinical trial results reported at this year’s European Haematology Association (EHA) congress showed that a one-time treatment with exa-cel had a significant benefit in both SCD and thalassaemia patients. The post Vertex, CRISPR prep filing for gene-editing blood disorder therapy appeared first on.